Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort descending | Description |
---|---|---|---|---|---|---|---|---|
GRANISETRON HYDROCHLORIDE INJECTION | USP Reference standards <11> | First Supplement to USP40–NF35 | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of USP Granisetron Related Compound C RS: Change carboxamide. to: carboxamide hydrochloride. |
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION | ASSAY/Procedure | USP40–NF35 | 5251 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of Sample solution: Change 45-µm pore size. to: 0.45-µm pore size. |
DOBUTAMINE INJECTION | IDENTIFICATION/A. | USP39–NF34 | 3561 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Sample solution: Change 10 mg/mL of dobutamine hydrochloride in methanol, clarified by centrifugation to: Use the neat Injection. |
DOCETAXEL | IMPURITIES/Organic Impurities, Procedure 1 | Revision Bulletin (Official August 01, 2016) | Online | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Footnote c of Table 2: Change (2aR,4R,4aS,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4, 9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5,6-dione 12b… Read More |
MAGNESIUM ALUMINOMETASILICATE | ASSAY/Magnesium Oxide | USP39–NF34 | 7375 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Analysis: Change eriochrome black TS trituration to: eriochrome black T trituration |
GRANISETRON HYDROCHLORIDE TABLETS | USP Reference standards <11> | First Supplement to USP40–NF35 | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of USP Granisetron Related Compound C RS: Change carboxamide. to: carboxamide hydrochloride. |
PHENYTOIN ORAL SUSPENSION | IMPURITIES/Organic Impurities | USP40–NF35 | 5690 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Sample solution: Change 1 mg/mL of Oral Suspension in Diluent to: Nominally 1 mg/mL of phenytoin prepared as follows. Weigh and transfer a suitable volume of Oral Suspension to an appropriate volumetric flask. Add methanol to about 20% of the final flask volume… Read More |
EZETIMIBE | IMPURITIES/Organic Impurities, Procedure 1/System suitability/Suitability requirements | USP39–NF34 | 3840 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 2 of Resolution: Change Standard solution to: System suitability solution |
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | First Supplement to USP39–NF34 | 8101 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Change Buffer, Mobile phase, Diluent, and Sample solution: Prepare as directed in the Assay. to: Buffer, Mobile phase, and Diluent: Prepare as directed in the Assay. AND Add Sample solution: Use the Sample… Read More |
ALMOTRIPTAN TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official February 01, 2017) | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 4 of USP Almotriptan Related Compound B RS: Change ½C4H4O to: ½C4H4O4 |
PIOGLITAZONE AND METFORMIN HYDROCHLORIDE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP40–NF35 | 5720 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 3 of Standard solution: Change USP Metformin Hydrochloride RS in Diluent A to: USP Metformin Hydrochloride RS from the Metformin standard stock solution in Diluent A |
MYCOPHENOLATE MOFETIL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4957 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of USP Mycophenolate Mofetil Related Compound A RS: Change C23H31NO7 to: C22H29NO7 |
REAGENTS, INDICATORS AND SOLUTIONS | Solutions/Volumetric Solutions | Second Supplement to USP39–NF34 | 8458 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of 0.07 N Ferrous Ammonium Sulfate VS: Change In a 100-mL volumetric flask, to: In a 1000-mL volumetric flask, |
<127> FLOW CYTOMETRIC ENUMERATION OF CD34+ CELLS | SAMPLE PREPARATION/Table 1. Dot Plot Descriptions and Gating Instructions | USP40–NF35 | 216 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Column 4 for Step 6: Add • For counting bead enumeration, proceed to either Step 7 or Step 8 according to the recommendations of the bead manufacturer. |
POLYETHYLENE GLYCOL 3350 | SPECIFIC TESTS/Apparent Weight-Average Molecular Weight and Polydispersity | USP40–NF35 | 5745 | 26-May-2017 | 1-Jun-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Standard solution: Change Standard solution: 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in Mobilephase. Pass a portion of the solution to: Standard solutions: Prepare 1.0… Read More |
MYCOPHENOLATE MOFETIL FOR INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP39–NF34 | 4960 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 5 of Mycophenolate Mofetil Related Compound A RS: Change C23H31NO7 to: C22H29NO7 |
MAGNESIUM ALUMINUM SILICATE | SPECIFIC TESTS/Viscosity/Acceptance criteria | Second Supplement to USP39–NF34 | 8558 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Type IA: Change 225–600 to: 225–600mPa · s AND Line 1 of Type IB: Change 150–450 to: 150–450 mPa · s AND Line 1 of Type IC: Change 800–2200 to: 800–2200 mPa · s AND Line 1 of Type IIA: Change 100–300 to: … Read More |
NAPROXEN SODIUM TABLETS | IMPURITIES/Organic Impurities | First Supplement to USP41–NF36 | 8363 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the System suitability solution: Change 0.5 mg/mL of USP Naproxen Sodium RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in Diluent, from Standard stock solution 1 and Standard stock solution 2, respectively to: 0.5… Read More |
CUPRIC SULFATE INJECTION | Assay | USP41–NF36 | 1112 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 8 of Assay preparation: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride content of this flask to 13.5 mg. |
OCTOCRYLENE | SPECIFIC TESTS/Acidity | First Supplement to USP41–NF36 | 8379 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 1 of Acceptance criteria: Change NMT 0.18 mL of Titrant is required to: NMT 0.18 mL of Titrant/g is required |
FLUTICASONE PROPIONATE INHALATION POWDER | IMPURITIES/Organic Impurities/System suitability | USP41–NF36 | 1836 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the Tailing factor: Change NLT 1.3 to: NMT 1.3 |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 8 | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change CS = concentration of oxybutynin chloride in the Standard solution (mg/mL) to: CS = concentration of USP Oxybutynin Chloride RS in the Standard… Read More |
GLUTARAL CONCENTRATE | ASSAY/Procedure | USP41–NF36 | 1960 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change W = weight of Concentrate taken (g) to: W = nominal weight of glutaral taken (g) |
LIDOCAINE | ASSAY/Procedure | First Supplement to USP41–NF36 | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the new USP-NF ONLINE platform only. Line 2 of Standard solution: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of Sample solution: Change 1 N sodium hydroxide, to: 1 N… Read More |
AZEOTROPIC ISOPROPYL ALCOHOL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP41–NF36 | 2257 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 1 of USP 2-Propanol System Suitability RS: Change It contains 0.1% of each of the following: ethyl ether, acetone, isopropyl alcohol, diisopropyl ether, 1-propanol, and 2-butanol. to: It is a mixture of the following: ethyl ether (0.1%), acetone (0.1… Read More |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | ASSAY/Procedure | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In System suitability: Add [Note—The relative retention times for oxybutynin and oxybutynin related compound A are about 1.0 and 1.6,… Read More |
METOPROLOL TARTRATE | CHEMICAL INFORMATION | USP41–NF36 | 2712 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 4: Change (±)-1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol l-(+)-tartrate (2:1) (salt); 1-(Isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanol (2:1) dextro-tartrate salt to: (±)-1-(… Read More |
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities | Revision Bulletin (Official April 01, 2018) | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the Revision Bulletin posted on www.uspnf.com only. In the variable definition list in Analysis: Change CU = nominal concentration of the Sample solution (mg… Read More |
FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 4309 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. C36H43NO6 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6… Read More |
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution Test 1 | USP41–NF36 | 3157 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the Analysis: Change Result = (rU/rS) × CS × (Mr1/Mr2) × V × (100/L) to: Result = (rU/rS) × CS × (Mr1/Mr2) × V × (100/L) × D … Read More |
PERINDOPRIL ERBUMINE | IMPURITIES/Limit of Perindopril Related Compound I/System suitability | USP40–NF35 | 5644 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 3: Add [Note—The relative retention times for perindopril and perindopril related compound I are 1.0 and 1.6, respectively.] |
AMLODIPINE AND ATORVASTATIN TABLETS | DEFINITION | First Supplement to USP41–NF36 | 8270 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 4: Change (C33H34FN2O5) to: (C33H35FN2O5) |
ALLOPURINOL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP41–NF36 | 121 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 3 of USP Allopurinol Related Compound A RS: Change (C5H6N4O)2 · H2SO4 350.32 to: (C4H6N4O)2 · H2SO4 350.31 |
SALMETEROL INHALATION POWDER | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP40–NF35 | 6096 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. C36H43NO6 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6… Read More |
AMLODIPINE AND ATORVASTATIN TABLETS | ASSAY/Procedure | First Supplement to USP41–NF36 | 8270 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the second Calculate statement in Analysis: Change (C33H34FN2O5) to: (C33H35FN2O5) |
CIPROFLOXACIN AND DEXAMETHASONE OTIC SUSPENSION | IMPURITIES | USP41–NF36 | 951 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list of Ciprofloxacin Related Compounds/Analysis: Change CU = nominal concentration of ciprofloxacin in the Otic Suspension (mg/mL) to: CU = nominal… Read More |
<661.1> PLASTIC MATERIALS OF CONSTRUCTION | TEST METHODS/Tin in Non-Tin-Stabilized Materials | USP41–NF36 | 6403 | 30-Mar-2018 | 1-Apr-2018 | USP42–NF37 | USP42–NF37 | Line 3 of Sample solution: Change If the solution is not colorless, add the sodium sulfate to: If the solution is not colorless, add the sodium sulfite |
AMLODIPINE AND ATORVASTATIN TABLETS | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP41–NF36 | 8270 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the second Calculate statement in Analysis: Change (C33H34FN2O5) to: (C33H35FN2O5) AND In Tolerances: Change (C33H… Read More |
CUPRIC CHLORIDE | ASSAY/Procedure | USP41–NF36 | 1109 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 1 of Analysis: Change To the Sample solution to: To 50 mL of the Sample solution |
ACAMPROSATE CALCIUM | IMPURITIES/Limit of Acamprosate Related Compound A | First Supplement to USP41–NF36 | 8263 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | In the variable definition list in Analysis: Change CS = concentration of USP Acamprosate Calcium Related Compound A RS in the Standard solution (µg/mL) to: CS = concentration of USP Acamprosate Related… Read More |
CUPRIC CHLORIDE INJECTION | ASSAY/Procedure | USP41–NF36 | 1111 | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | Line 3 of Sample solution: Change to bring the total sodium content of this flask to 13.5 mg. to: to bring the total sodium chloride content of this flask to 13.5 mg. |
METHYLENE BLUE | IMPURITIES/Organic Impurities | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In footnote a in Table 2: Change 3-(Dimethylamino)-7-(methylamino)-phenothiazine-5-ium chloride. to: 3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride. |
METHYLENE BLUE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Azure B RS: Change 3-(Dimethylamino)-7-(methylamino)-phenothiazine-5-ium chloride. to: 3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride. |
ECONAZOLE NITRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Econazole Related Compound C RS: Change 1-(4-Chlorobenzyl)-3-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium nitrate (salt). C25H21Cl14N3O4 569.… Read More |
ROCURONIUM BROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | Change 609.68 to: 609.69 |
ROCURONIUM BROMIDE | IMPURITIES/Organic Impurities | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | In footnote b of Table 1: Change 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstan-3α,17β-diol. to: 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstane-3α,17β-diol. |
AZITHROMYCIN FOR INJECTION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In USP Reference Standards 〈11〉/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin N-oxide RS: Change 764.98 to: 765.00 AND In USP N-Demethylazithromycin RS: Change 734.96 to: 734.97… Read More |
AZITHROMYCIN FOR INJECTION | IMPURITIES | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In footnote m in Table 2: Change (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-… Read More |